1st Quarter - Termination Amendment — CEPHEID for CEPHEID (2017)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$12,300

Expense method

A: Lobbying Disclosure Act definitions

Terminated

Jan 26, 2017

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
1st Quarter - Termination	May 11, 2017	$25,000	Replaced
1st Quarter - Report	May 11, 2017	$12,300	Replaced
1st Quarter - Termination Amendment (this page)	Mar 23, 2018	$12,300	Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

IVD regulation reform, antimicrobial resistance policies, CMS coverage and ;payment issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

CMS coverage determination process, delay in PAMA implementation

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); White House Office; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

IVD regulatory reform, CMS coverage determination process

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC)

Science/Technology SCI

IVD regulatory reform, point of care testing

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: SENATE; Agency for Healthcare Research & Quality (AHRQ); Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC); White House Office; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.